Facing CMS sanctions, lab industry insiders ponder the firm's options in seeking to launch a Zika virus assay with emergency use authorization on its upcoming miniLab platform.
At the American Association for Clinical Chemistry meeting, Theranos CEO Elizabeth Holmes said her company is working on third-party review and publications of the firm's technologies and tests.
Researchers led by MIT's Jim Collins have built upon their paper-based Ebola test and are hoping to find a partner to help scale production and manufacturing of the test.
The company plans to add assays for Group B Streptococcus, Clostridium difficile, and norovirus in 2016 to complement its existing meningitis test.
The test is the first in the Dublin, Ireland-based firm's pipeline of infectious disease assays that use loop-mediated isothermal amplification.
Lumora's MDx technology for the clinical and industrial sectors will be merged with ERBA Mannheim's IVD testing business in a wide range of market segments.
The 3M Molecular Detection Assay 2 – Listeria monocytogenes is 30 percent faster than the first-generation test.
Meridian's Diagnostics segment grew 2 percent lifted by a 10 percent increase in revenues from the illumigene molecular product line.
The assay is the first on the firm's isothermal nucleic acid amplification-based platform.
At AGBT, the firm discussed the launch of the Proton PII chip, an update of the PI chip, and sample prep improvements.
In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.
Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.
Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.
In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.